Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC)

Barclays PLC raised its holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) by 283.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 61,945 shares of the company’s stock after purchasing an additional 45,797 shares during the period. Barclays PLC owned 0.07% of Century Therapeutics worth $106,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Century Therapeutics by 3.5% in the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after purchasing an additional 32,614 shares in the last quarter. State Street Corp lifted its holdings in shares of Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after purchasing an additional 57,323 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after buying an additional 18,828 shares during the period. Wellington Management Group LLP purchased a new position in shares of Century Therapeutics during the third quarter valued at approximately $284,000. Finally, SG Americas Securities LLC purchased a new position in shares of Century Therapeutics during the third quarter valued at approximately $27,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on IPSC shares. Guggenheim reissued a “buy” rating on shares of Century Therapeutics in a research note on Wednesday. Piper Sandler reduced their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Chardan Capital reduced their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Stock Up 2.1 %

Century Therapeutics stock opened at $0.91 on Friday. Century Therapeutics, Inc. has a 52-week low of $0.86 and a 52-week high of $5.51. The firm has a fifty day moving average of $1.18 and a 200-day moving average of $1.56. The firm has a market capitalization of $77.38 million, a P/E ratio of -0.49 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. The business had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.47 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same period last year, the business earned ($0.55) EPS. On average, research analysts expect that Century Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.